Eye Health News and Research

Latest Eye Health News and Research

Promedior raises $12M in Series C financing

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.

16 Mar 2010

Perrigo introduces generic Zaditor

Perrigo Company today announced that it has begun shipping Ketotifen Fumarate ophthalmic solution, 0.025%, a generic version of Zaditor™.

15 Mar 2010

Inspire Pharmaceuticals reports results of two AZASITE Phase 2 clinical trials for blepharitis

Inspire Pharmaceuticals, Inc. announced today the results from two Phase 2 clinical trials with AZASITE (azithromycin ophthalmic solution) 1% for the treatment of blepharitis. Inspire will conduct additional clinical work to continue pursuing a potential indication for treatment of anterior and posterior forms of blepharitis.

15 Mar 2010

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

On March 10-11, 2010, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) -- including the Pulmonary-Allergy Drugs and the Drug Safety and Risk Management Advisory Committees -- discussed the design of post-marketing safety studies for long-acting beta-agonist (LABA)-containing products in the U.S., including SYMBICORT® (budesonide/formoterol fumarate dihydrate).

12 Mar 2010

New MMMCC center improves patients’ access to medical marijuana

Marijuana is not just for brownies anymore. It has touched the lives of thousands of Michigan residents who are struggling with chronic pain, severe nausea, seizures, spasms or wasting syndrome.

12 Mar 2010

OXiGENE signs definitive agreement to sell Common Stock

OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has entered into a definitive agreement with certain institutional investors to sell 6,578,945 shares of its Common Stock and separate series of warrants to purchase Common Stock in a private placement.

12 Mar 2010

Study explores incidence of eating disorders among type 1 diabetic patients

Diabetics, under the gun to better manage their disease by controlling their food intake and weight, may find themselves in the sticky wicket of needing treatment that makes them hungry, researchers said.

12 Mar 2010

Age-related macular degeneration affects central vision in older Americans

Indianapolis resident Harry Traugott was an active retiree, participating in community events, driving and even teaching English as a second language at two community centers. He’d been diagnosed with age-related macular degeneration (AMD), but the disease had not caused significant vision loss. It wasn’t until he had trouble seeing while driving, watching television

11 Mar 2010

StemCells reports net loss of $5.23M for fourth-quarter fiscal 2009

StemCells, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. The Company's results include the operations of Stem Cell Sciences Plc (SCS) since April 1, 2009.

11 Mar 2010

Auditory cortex development becomes vulnerable if it does not receive appropriate stimulation at right time

Hearing scientist Daniel Polley, Ph.D., an investigator at Massachusetts Eye and Ear Infirmary's Eaton-Peabody Laboratories of Auditory Physiology, has gained new insight into why a relatively short-term hearing deprivation during childhood may lead to persistent hearing deficits, long after hearing is restored to normal.

11 Mar 2010

Proposed rule to exchange EHR's without patients' consent will affect Americans' health privacy

The proposed federal rule to create and exchange electronic health records without patients' consent threatens Americans' health privacy, warns the Institute for Health Freedom.

11 Mar 2010

Bioness announces two agreements to distribute new devices for patients with neurological impairment

Bioness Inc., a leading neuromodulation company, announced today two agreements to distribute new devices for patients experiencing neurological impairment. Through the agreements with Performance Enterprises and Aretech™, LLC, Bioness is now distributing the Dynavision D2™ Visuomotor Training System and the ZeroG™ Overground Gait and Balance Training System to rehabilitation centers and hospitals.

11 Mar 2010

$TLCVision to incorporate TearLab Osmolarity System to study DED in refractive surgery centers$

TLCVision to incorporate TearLab Osmolarity System to study DED in refractive surgery centers

OccuLogix, Inc., dba TearLab Corporation, announced today that TLCVision Corporation, North America's premier eye care services company, will be incorporating the TearLab™ Osmolarity System in eight of its U.S. refractive surgery centers to study Dry Eye Disease symptoms as they relate to LASIK surgery.

11 Mar 2010

QLT announces results from Phase II clinical trials and device study for PPDS

QLT Inc. today announced results from Phase II clinical trials and a device study for the punctal plug delivery system (PPDS). These studies are part of a development program that is being conducted by QLT's wholly-owned subsidiary, QLT Plug Delivery, Inc. QLT also announced its plans to expand the program to evaluate a second drug for a new target indication.

11 Mar 2010

FDA approves Abbott's TECNIS Multifocal 1-Piece intraocular lens for cataract patients

Abbott announced today it has received U.S. Food and Drug Administration approval for the TECNIS® Multifocal 1-Piece intraocular lens (IOL) for cataract patients with and without presbyopia.

10 Mar 2010

TNS acquires license to Ergothioneine Transporter from University of Cologne

Total Nutraceutical Solutions, Inc. announced that the company has acquired from the University of Cologne, Cologne, Germany, an exclusive license agreement on the invention entitled “Ergothioneine Transporter,” owned by the University.

10 Mar 2010

Lowering levels of Coonexin46 with use of siRNA will help prevent tumor formation

What began as research into how diabetics could possibly preserve their eyesight has led to findings that could prolong the vision of children afflicted with retinoblastoma.

10 Mar 2010

Senator Bond recognized for providing leadership on health care policy issues

Sen. Christopher "Kit" Bond (R-MO) has been recognized for providing important leadership on health care policy issues and working to increase access to vision and eye health care by doctors of optometry from his state and their national organization, the American Optometric Association.

10 Mar 2010

Celebrity supports fundraising event for cancer research

Kimberly Wyatt from the "Pussycat Dolls" has shone brightly to promote Cancer Research UK's latest fundraising event by posing in a bespoke, illuminated dress designed especially for her.

10 Mar 2010

Aton Pharma introduces authorized generic version of Timoptic-XE

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has launched an authorized generic version of its Timoptic-XE® (timolol maleate ophthalmic gel forming solution). Timoptic-XE is a non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Aton also announced that it will continue to make available branded Timoptic-XE.

9 Mar 2010

Eye Health News and Research

Latest Eye Health News and Research

Promedior raises $12M in Series C financing

Perrigo introduces generic Zaditor

Inspire Pharmaceuticals reports results of two AZASITE Phase 2 clinical trials for blepharitis

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

New MMMCC center improves patients’ access to medical marijuana

OXiGENE signs definitive agreement to sell Common Stock

Study explores incidence of eating disorders among type 1 diabetic patients

Age-related macular degeneration affects central vision in older Americans

StemCells reports net loss of $5.23M for fourth-quarter fiscal 2009

Auditory cortex development becomes vulnerable if it does not receive appropriate stimulation at right time

Proposed rule to exchange EHR's without patients' consent will affect Americans' health privacy

Bioness announces two agreements to distribute new devices for patients with neurological impairment

TLCVision to incorporate TearLab Osmolarity System to study DED in refractive surgery centers

QLT announces results from Phase II clinical trials and device study for PPDS

FDA approves Abbott's TECNIS Multifocal 1-Piece intraocular lens for cataract patients

TNS acquires license to Ergothioneine Transporter from University of Cologne

Lowering levels of Coonexin46 with use of siRNA will help prevent tumor formation

Senator Bond recognized for providing leadership on health care policy issues

Celebrity supports fundraising event for cancer research

Aton Pharma introduces authorized generic version of Timoptic-XE

Genetics & Genomics - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Eye Health News and Research

Latest Eye Health News and Research

Genetics & Genomics - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in